Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer

JJ Cunningham, JS Brown, RA Gatenby… - Journal of theoretical …, 2018 - Elsevier
In metastatic castrate resistant prostate cancer (mCRPC), abiraterone is conventionally
administered continuously at maximal tolerated dose until treatment failure. The majority of …
被引用次数：112 相关文章

[引用][C] Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer

JJ Cunningham, JS Brown, RA Gatenby… - Journal of Theoretical …, 2018 - cir.nii.ac.jp
Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate
cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer.

JJ Cunningham, JS Brown, RA Gatenby… - Journal of Theoretical …, 2018 - europepmc.org
In metastatic castrate resistant prostate cancer (mCRPC), abiraterone is conventionally
administered continuously at maximal tolerated dose until treatment failure. The majority of …

Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer

JJ Cunningham, JS Brown… - Journal of …, 2018 - cris.maastrichtuniversity.nl
In metastatic castrate resistant prostate cancer (mCRPC), abiraterone is conventionally
administered continuously at maximal tolerated dose until treatment failure. The majority of …

Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer

JJ Cunningham, JS Brown… - Journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
In metastatic castrate resistant prostate cancer (mCRPC), abiraterone is conventionally
administered continuously at maximal tolerated dose until treatment failure. The majority of …

Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer

JJ Cunningham, JS Brown, RA Gatenby… - Journal of Theoretical …, 2018 - research.tudelft.nl
In metastatic castrate resistant prostate cancer (mCRPC), abiraterone is conventionally
administered continuously at maximal tolerated dose until treatment failure. The majority of …

Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer

JJ Cunningham, JS Brown… - Journal of …, 2018 - ui.adsabs.harvard.edu
In metastatic castrate resistant prostate cancer (mCRPC), abiraterone is conventionally
administered continuously at maximal tolerated dose until treatment failure. The majority of …